Search

Your search keyword '"Richardson, Paul G."' showing total 3,909 results
Start Over Author "Richardson, Paul G."
3,909 results on '"Richardson, Paul G."'

152. Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy.

Author

Mo, Clifton C., Hartley-Brown, Monique A., Midha, Shonali, and Richardson, Paul G.

Subjects
STEM cell transplantation, MULTIPLE myeloma treatment, MULTIPLE myeloma diagnosis, MELPHALAN, AUTOGRAFTS, TREATMENT effectiveness, PROGRESSION-free survival, INDUCTION chemotherapy, OVERALL survival
Abstract

Simple Summary: Patients who are diagnosed with multiple myeloma are given an initial sequence of treatments that usually, for those who are young and fit enough, includes high-dose melphalan followed by autologous stem cell transplantation. This has contributed to the improvement in survival seen over the past 30 years. However, high-dose melphalan has significant limitations, including short-term side effects and longer-term issues such as an increased risk of developing secondary hematologic malignancies including leukemia. There are now numerous highly efficacious combination regimens for initial treatment that result in increasingly large proportions of patients achieving deep responses with no evidence of minimal residual disease. Moreover, large, randomized studies using these regimens have shown no benefit in overall survival after receiving high-dose melphalan with stem cell transplantation. There is thus a growing rationale for selected eligible patients to defer receiving high-dose melphalan and stem cell transplantation until potentially needed in a subsequent line of treatment. The standards of care for the initial treatment of patients with newly diagnosed multiple myeloma (NDMM) who are eligible for high-dose melphalan and autologous stem cell transplantation (HDM-ASCT) include highly active triplet and quadruplet regimens based on proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. These regimens are resulting in improved outcomes and increasingly high rates of minimal residual disease (MRD)-negative responses without HDM-ASCT as part of the upfront therapy. Furthermore, recent randomized studies have shown that, while transplant-based approaches as a frontline therapy result in significantly longer progression-free survival compared to non-transplant approaches, this has not translated into an overall survival benefit. Given these developments, and in the context of the treatment burden of undergoing HDM-ASCT, in addition to the acute toxicities and long-term sequelae of HDM, which are associated with the genotoxicity of melphalan, there is an increasing rationale for considering deferring upfront HDM-ASCT in select transplant-eligible patients and saving it as a treatment option for later salvage therapy. Here, we review the latest clinical trial data on upfront or deferred HDM-ASCT and on the activity of quadruplet induction regimens, including rates of MRD-negative responses, and summarize emerging treatment approaches in the upfront setting such as the use of MRD-directed therapy and alternatives to HDM-ASCT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

153. Supplementary Figure 4 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Author

Fabre, Claire, primary, Mimura, Naoya, primary, Bobb, Kathryn, primary, Kong, Sun-Young, primary, Gorgun, Güllü, primary, Cirstea, Diana, primary, Hu, Yiguo, primary, Minami, Jiro, primary, Ohguchi, Hiroto, primary, Zhang, Jie, primary, Meshulam, Jeffrey, primary, Carrasco, Ruben D., primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Hideshima, Teru, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

154. Figure S3 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma

Author

Waldschmidt, Johannes M., primary, Kloeber, Jake A., primary, Anand, Praveen, primary, Frede, Julia, primary, Kokkalis, Antonis, primary, Dimitrova, Valeriya, primary, Potdar, Sayalee, primary, Nair, Monica S., primary, Vijaykumar, Tushara, primary, Im, Nam Gyu, primary, Guillaumet-Adkins, Amy, primary, Chopra, Nitish, primary, Stuart, Hannah, primary, Budano, Lillian, primary, Sotudeh, Noori, primary, Guo, Guangwu, primary, Grassberger, Clemens, primary, Yee, Andrew J., primary, Laubach, Jacob P., primary, Richardson, Paul G., primary, Anderson, Kenneth C., primary, Raje, Noopur S., primary, Knoechel, Birgit, primary, and Lohr, Jens G., primary

Published
2023
Full Text
View/download PDF

155. Table S2 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma

Author

Waldschmidt, Johannes M., primary, Kloeber, Jake A., primary, Anand, Praveen, primary, Frede, Julia, primary, Kokkalis, Antonis, primary, Dimitrova, Valeriya, primary, Potdar, Sayalee, primary, Nair, Monica S., primary, Vijaykumar, Tushara, primary, Im, Nam Gyu, primary, Guillaumet-Adkins, Amy, primary, Chopra, Nitish, primary, Stuart, Hannah, primary, Budano, Lillian, primary, Sotudeh, Noori, primary, Guo, Guangwu, primary, Grassberger, Clemens, primary, Yee, Andrew J., primary, Laubach, Jacob P., primary, Richardson, Paul G., primary, Anderson, Kenneth C., primary, Raje, Noopur S., primary, Knoechel, Birgit, primary, and Lohr, Jens G., primary

Published
2023
Full Text
View/download PDF

156. Supplementary Data from Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

Author

Ooi, Melissa G., primary, Hayden, Patrick J., primary, Kotoula, Vassiliki, primary, McMillin, Douglas W., primary, Charalambous, Elpida, primary, Daskalaki, Emily, primary, Raje, Noopur S., primary, Munshi, Nikhil C., primary, Chauhan, Dharminder, primary, Hideshima, Teru, primary, Buon, Leutz, primary, Clynes, Martin, primary, O'Gorman, Peter, primary, Richardson, Paul G., primary, Mitsiades, Constantine S., primary, Anderson, Kenneth C., primary, and Mitsiades, Nicholas, primary

Published
2023
Full Text
View/download PDF

157. Supplemental Table 3 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

158. Supplementary Figure Legends from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma

Author

Waldschmidt, Johannes M., primary, Kloeber, Jake A., primary, Anand, Praveen, primary, Frede, Julia, primary, Kokkalis, Antonis, primary, Dimitrova, Valeriya, primary, Potdar, Sayalee, primary, Nair, Monica S., primary, Vijaykumar, Tushara, primary, Im, Nam Gyu, primary, Guillaumet-Adkins, Amy, primary, Chopra, Nitish, primary, Stuart, Hannah, primary, Budano, Lillian, primary, Sotudeh, Noori, primary, Guo, Guangwu, primary, Grassberger, Clemens, primary, Yee, Andrew J., primary, Laubach, Jacob P., primary, Richardson, Paul G., primary, Anderson, Kenneth C., primary, Raje, Noopur S., primary, Knoechel, Birgit, primary, and Lohr, Jens G., primary

Published
2023
Full Text
View/download PDF

159. Supplemental Table 2 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

160. Supplemental Figure Legend from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

161. Supplementary Data 3 from A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

Author

Ghobrial, Irene M., primary, Liu, Chia-Jen, primary, Redd, Robert A., primary, Perez, Raymond P., primary, Baz, Rachid, primary, Zavidij, Oksana, primary, Sklavenitis-Pistofidis, Romanos, primary, Richardson, Paul G., primary, Anderson, Kenneth C., primary, Laubach, Jacob, primary, Henrick, Patrick, primary, Savell, Alexandra, primary, Reyes, Kaitlen, primary, Hornburg, Kalvis, primary, Chuma, Stacey, primary, Sabbatini, Peter, primary, Robbins, Michael D., primary, and Becker, Pamela S., primary

Published
2023
Full Text
View/download PDF

162. SI from Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Author

Tang, Min, primary, Zhao, Rui, primary, van de Velde, Helgi, primary, Tross, Jennifer G., primary, Mitsiades, Constantine, primary, Viselli, Suzanne, primary, Neuwirth, Rachel, primary, Esseltine, Dixie-Lee, primary, Anderson, Kenneth, primary, Ghobrial, Irene M., primary, San Miguel, Jesús F., primary, Richardson, Paul G., primary, Tomasson, Michael H., primary, and Michor, Franziska, primary

Published
2023
Full Text
View/download PDF

163. Supplementary Figure 2 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Author

Fabre, Claire, primary, Mimura, Naoya, primary, Bobb, Kathryn, primary, Kong, Sun-Young, primary, Gorgun, Güllü, primary, Cirstea, Diana, primary, Hu, Yiguo, primary, Minami, Jiro, primary, Ohguchi, Hiroto, primary, Zhang, Jie, primary, Meshulam, Jeffrey, primary, Carrasco, Ruben D., primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Hideshima, Teru, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

164. SI Tables from Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Author

Tang, Min, primary, Zhao, Rui, primary, van de Velde, Helgi, primary, Tross, Jennifer G., primary, Mitsiades, Constantine, primary, Viselli, Suzanne, primary, Neuwirth, Rachel, primary, Esseltine, Dixie-Lee, primary, Anderson, Kenneth, primary, Ghobrial, Irene M., primary, San Miguel, Jesús F., primary, Richardson, Paul G., primary, Tomasson, Michael H., primary, and Michor, Franziska, primary

Published
2023
Full Text
View/download PDF

165. Supplementary Figure Legend from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Author

Fabre, Claire, primary, Mimura, Naoya, primary, Bobb, Kathryn, primary, Kong, Sun-Young, primary, Gorgun, Güllü, primary, Cirstea, Diana, primary, Hu, Yiguo, primary, Minami, Jiro, primary, Ohguchi, Hiroto, primary, Zhang, Jie, primary, Meshulam, Jeffrey, primary, Carrasco, Ruben D., primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Hideshima, Teru, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

166. Supplementary Figure and Method from Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Author

Görgün, Güllü, primary, Samur, Mehmet K., primary, Cowens, Kristen B., primary, Paula, Steven, primary, Bianchi, Giada, primary, Anderson, Julie E., primary, White, Randie E., primary, Singh, Ahaana, primary, Ohguchi, Hiroto, primary, Suzuki, Rikio, primary, Kikuchi, Shohei, primary, Harada, Takeshi, primary, Hideshima, Teru, primary, Tai, Yu-Tzu, primary, Laubach, Jacob P., primary, Raje, Noopur, primary, Magrangeas, Florence, primary, Minvielle, Stephane, primary, Avet-Loiseau, Herve, primary, Munshi, Nikhil C., primary, Dorfman, David M., primary, Richardson, Paul G., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

168. Supplementary Table 3 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Author

Fabre, Claire, primary, Mimura, Naoya, primary, Bobb, Kathryn, primary, Kong, Sun-Young, primary, Gorgun, Güllü, primary, Cirstea, Diana, primary, Hu, Yiguo, primary, Minami, Jiro, primary, Ohguchi, Hiroto, primary, Zhang, Jie, primary, Meshulam, Jeffrey, primary, Carrasco, Ruben D., primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Hideshima, Teru, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

169. Supplementary Figure 5 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Author

Fabre, Claire, primary, Mimura, Naoya, primary, Bobb, Kathryn, primary, Kong, Sun-Young, primary, Gorgun, Güllü, primary, Cirstea, Diana, primary, Hu, Yiguo, primary, Minami, Jiro, primary, Ohguchi, Hiroto, primary, Zhang, Jie, primary, Meshulam, Jeffrey, primary, Carrasco, Ruben D., primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Hideshima, Teru, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

170. SI Figures from Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Author

Tang, Min, primary, Zhao, Rui, primary, van de Velde, Helgi, primary, Tross, Jennifer G., primary, Mitsiades, Constantine, primary, Viselli, Suzanne, primary, Neuwirth, Rachel, primary, Esseltine, Dixie-Lee, primary, Anderson, Kenneth, primary, Ghobrial, Irene M., primary, San Miguel, Jesús F., primary, Richardson, Paul G., primary, Tomasson, Michael H., primary, and Michor, Franziska, primary

Published
2023
Full Text
View/download PDF

171. Supplementary Figure 1 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Author

Fabre, Claire, primary, Mimura, Naoya, primary, Bobb, Kathryn, primary, Kong, Sun-Young, primary, Gorgun, Güllü, primary, Cirstea, Diana, primary, Hu, Yiguo, primary, Minami, Jiro, primary, Ohguchi, Hiroto, primary, Zhang, Jie, primary, Meshulam, Jeffrey, primary, Carrasco, Ruben D., primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Hideshima, Teru, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

172. Data from Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Author

Görgün, Güllü, primary, Samur, Mehmet K., primary, Cowens, Kristen B., primary, Paula, Steven, primary, Bianchi, Giada, primary, Anderson, Julie E., primary, White, Randie E., primary, Singh, Ahaana, primary, Ohguchi, Hiroto, primary, Suzuki, Rikio, primary, Kikuchi, Shohei, primary, Harada, Takeshi, primary, Hideshima, Teru, primary, Tai, Yu-Tzu, primary, Laubach, Jacob P., primary, Raje, Noopur, primary, Magrangeas, Florence, primary, Minvielle, Stephane, primary, Avet-Loiseau, Herve, primary, Munshi, Nikhil C., primary, Dorfman, David M., primary, Richardson, Paul G., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

173. Supplemental Figure from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

174. Supplemental Table 1 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

175. Supplementary Figure 8 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

176. Supplementary Figure 3b from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

177. Supplementary Figures 1-7 from Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

Author

McMillin, Douglas W., primary, Ooi, Melissa, primary, Delmore, Jake, primary, Negri, Joseph, primary, Hayden, Patrick, primary, Mitsiades, Nicolas, primary, Jakubikova, Jana, primary, Maira, Sauveur-Michel, primary, Garcia-Echeverria, Carlos, primary, Schlossman, Robert, primary, Munshi, Nikhil C., primary, Richardson, Paul G., primary, Anderson, Kenneth C., primary, and Mitsiades, Constantine S., primary

Published
2023
Full Text
View/download PDF

178. Supplementary Figures 1 - 10, Tables 1 - 4 from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

Author

Mimura, Naoya, primary, Hideshima, Teru, primary, Shimomura, Toshiyasu, primary, Suzuki, Rikio, primary, Ohguchi, Hiroto, primary, Rizq, Ola, primary, Kikuchi, Shohei, primary, Yoshida, Yasuhiro, primary, Cottini, Francesca, primary, Jakubikova, Jana, primary, Cirstea, Diana, primary, Gorgun, Gullu, primary, Minami, Jiro, primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Utsugi, Teruhiro, primary, Iwama, Atsushi, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

179. Supplementary Table 1 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

180. Data from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

Author

Mimura, Naoya, primary, Hideshima, Teru, primary, Shimomura, Toshiyasu, primary, Suzuki, Rikio, primary, Ohguchi, Hiroto, primary, Rizq, Ola, primary, Kikuchi, Shohei, primary, Yoshida, Yasuhiro, primary, Cottini, Francesca, primary, Jakubikova, Jana, primary, Cirstea, Diana, primary, Gorgun, Gullu, primary, Minami, Jiro, primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Utsugi, Teruhiro, primary, Iwama, Atsushi, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

181. Supplementary Methods, Figure Legends 1-8 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

182. Supplementary Figure 2 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

183. Supplementary Methods from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

Author

Mimura, Naoya, primary, Hideshima, Teru, primary, Shimomura, Toshiyasu, primary, Suzuki, Rikio, primary, Ohguchi, Hiroto, primary, Rizq, Ola, primary, Kikuchi, Shohei, primary, Yoshida, Yasuhiro, primary, Cottini, Francesca, primary, Jakubikova, Jana, primary, Cirstea, Diana, primary, Gorgun, Gullu, primary, Minami, Jiro, primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Utsugi, Teruhiro, primary, Iwama, Atsushi, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

184. Supplementary Figure 5 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

185. Supplementary Figure 6 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

186. Supplementary Figure Legends from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

Author

Mimura, Naoya, primary, Hideshima, Teru, primary, Shimomura, Toshiyasu, primary, Suzuki, Rikio, primary, Ohguchi, Hiroto, primary, Rizq, Ola, primary, Kikuchi, Shohei, primary, Yoshida, Yasuhiro, primary, Cottini, Francesca, primary, Jakubikova, Jana, primary, Cirstea, Diana, primary, Gorgun, Gullu, primary, Minami, Jiro, primary, Tai, Yu-Tzu, primary, Richardson, Paul G., primary, Utsugi, Teruhiro, primary, Iwama, Atsushi, primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

187. Supplementary Figure 4 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

188. Supplementary Figure 7 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

189. Supplementary Figure 1 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

190. Supplementary Table 2 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Author

Mitsiades, Constantine S., primary, Ocio, Enrique M., primary, Pandiella, Atanasio, primary, Maiso, Patricia, primary, Gajate, Consuelo, primary, Garayoa, Mercedes, primary, Vilanova, David, primary, Montero, Juan Carlos, primary, Mitsiades, Nicholas, primary, McMullan, Ciaran J., primary, Munshi, Nikhil C., primary, Hideshima, Teru, primary, Chauhan, Dharminder, primary, Aviles, Pablo, primary, Otero, Gabriel, primary, Faircloth, Glynn, primary, Mateos, M. Victoria, primary, Richardson, Paul G., primary, Mollinedo, Faustino, primary, San-Miguel, Jesus F., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

191. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

Author

Dimopoulos, Meletios A., primary, Oriol, Albert, additional, Nahi, Hareth, additional, San-Miguel, Jesus, additional, Bahlis, Nizar J., additional, Usmani, Saad Z., additional, Rabin, Neil, additional, Orlowski, Robert Z., additional, Suzuki, Kenshi, additional, Plesner, Torben, additional, Yoon, Sung-Soo, additional, Ben Yehuda, Dina, additional, Richardson, Paul G., additional, Goldschmidt, Hartmut, additional, Reece, Donna, additional, Ahmadi, Tahamtan, additional, Qin, Xiang, additional, Garvin Mayo, Wendy, additional, Gai, Xue, additional, Carey, Jodi, additional, Carson, Robin, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

193. Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) and Lenalidomide (R) Maintenance to Progression in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Hassoun, Hani, primary, Jacobus, Susanna J, additional, Richardson, Paul G., additional, Zonder, Jeffrey, additional, Voorhees, Peter M., additional, Kaufman, Jonathan L., additional, Yee, Andrew J, additional, Scott, Emma C, additional, Torka, Pallawi, additional, Libby, Edward N., additional, Reeves, Brandi, additional, Wang, Michael L., additional, Anderson, Larry D., additional, Milner, Carter, additional, Gasparetto, Cristina, additional, Agha, Mounzer, additional, Khan, Dr. Abdullah, additional, Hurd, David D, additional, Avigan, David E., additional, Costello, Caitlin, additional, Jakubowiak, Andrzej, additional, Lonial, Sagar, additional, Raje, Noopur S, additional, Medvedova, Eva, additional, McCarthy, Dr. Philip L., additional, Orlowski, Robert Z., additional, Nadeem, Omar, additional, Laubach, Jacob, additional, Pasquini, Marcelo, additional, Giralt, Sergio, additional, Masone, Kelly, additional, Samur, Mehmet, additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Weller, Edie, additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2023
Full Text
View/download PDF

194. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Author

Dimopoulos, Meletios A., primary, Dytfeld, Dominik, additional, Grosicki, Sebastian, additional, Moreau, Philippe, additional, Takezako, Naoki, additional, Hori, Mitsuo, additional, Leleu, Xavier, additional, LeBlanc, Richard, additional, Suzuki, Kenshi, additional, Raab, Marc S., additional, Richardson, Paul G., additional, Popa McKiver, Mihaela, additional, Jou, Ying-Ming, additional, Yao, David, additional, Das, Prianka, additional, and San-Miguel, Jesús, additional

Published
2023
Full Text
View/download PDF

195. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

Author

Richardson, Paul G, Jagannath, Sundar, Moreau, Philippe, Jakubowiak, Andrzej J, Raab, Marc S, Facon, Thierry, Vij, Ravi, White, Darrell, Reece, Donna E, Benboubker, Lotfi, Zonder, Jeffrey, Tsao, L Claire, Anderson, Kenneth C, Bleickardt, Eric, Singhal, Anil K, and Lonial, Sagar

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results